[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Amgen Inc (AMGN)

Amgen Inc (AMGN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 190,419,776
  • Shares Outstanding, K 539,708
  • Annual Sales, $ 36,751 M
  • Annual Income, $ 7,711 M
  • EBIT $ 10,568 M
  • EBITDA $ 16,935 M
  • 60-Month Beta 0.42
  • Price/Sales 5.16
  • Price/Cash Flow 10.40
  • Price/Book 20.64

Options Overview Details

View History
  • Implied Volatility 28.21% (+0.95%)
  • Historical Volatility 25.94%
  • IV Percentile 65%
  • IV Rank 55.69%
  • IV High 35.00% on 04/07/26
  • IV Low 19.66% on 08/15/25
  • Expected Move (DTE 6) 8.42 (2.37%)
  • Put/Call Vol Ratio 0.32
  • Today's Volume 6,714
  • Volume Avg (30-Day) 7,143
  • Put/Call OI Ratio 0.77
  • Today's Open Interest 115,319
  • Open Int (30-Day) 122,036
  • Expected Range 347.45 to 364.29

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 36 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $5.55
  • Number of Estimates 11
  • High Estimate $5.77
  • Low Estimate $5.30
  • Prior Year $6.02
  • Growth Rate Est. (year over year) -7.81%

Price Performance

See More
Period Period Low Period High Performance
1-Month
322.30 +11.18%
on 06/02/26
362.27 -1.09%
on 06/26/26
+22.39 (+6.66%)
since 05/26/26
3-Month
320.52 +11.80%
on 05/05/26
362.27 -1.09%
on 06/26/26
+5.17 (+1.46%)
since 03/26/26
52-Week
269.77 +32.83%
on 09/26/25
391.29 -8.42%
on 03/02/26
+79.22 (+28.38%)
since 06/26/25

Most Recent Stories

More News
2 Healthcare Stocks to Consider Right Now and 1 We Brush Off

2 Healthcare Stocks to Consider Right Now and 1 We Brush Off

MEDP : 527.07 (+1.37%)
GDRX : 2.81 (+4.46%)
AMGN : 358.33 (+1.56%)
The Biotech Sector Looks Ready for a Multi-Year Breakout—Here's What to Watch.

The iShares Nasdaq Biotechnology ETF (IBB) is trading just 1.47% below its 52-week high, signaling a potential multi-year sector breakout.

IBB : 187.35 (+2.00%)
VRTX : 491.34 (+2.32%)
GILD : 127.70 (+3.12%)
AMGN : 358.33 (+1.56%)
How Is Biogen’s Stock Performance Compared to Other Biotech Stocks?

Biogen has recently outperformed its industry peers, and analysts remain reasonably upbeat about the stock’s prospects.

IBB : 187.35 (+2.00%)
AMGN : 358.33 (+1.56%)
BIIB : 216.03 (+6.97%)
2 S&P 500 Stocks with Competitive Advantages and 1 Facing Challenges

2 S&P 500 Stocks with Competitive Advantages and 1 Facing Challenges

COP : 105.96 (-0.42%)
HIG : 133.89 (+2.70%)
AMGN : 358.33 (+1.56%)
AMGEN PRESENTS NEW DATA ACROSS ITS CARDIOMETABOLIC PORTFOLIO AT AMERICAN DIABETES ASSOCIATION 86TH SCIENTIFIC SESSIONS

VESALIUS-CV Subgroup Results Show Repatha ® Reduces Risk of First Major Cardiovascular Events by 29% in People Living with High-Risk Diabetes

AMGN : 358.33 (+1.56%)
The Dow's Split Personality: Why Some Winners Soar While Others Drag Down the Dow

The oldest stock index in the world is suffering from a severe case of split personality. This internal friction has triggered a mechanical phenomenon, the likes of which I cannot recall, at least to...

NVDA : 192.53 (-1.64%)
AAPL : 283.78 (+3.14%)
$NASX : 25,297.62 (-0.24%)
CSCO : 113.77 (-4.37%)
CVX : 171.06 (-0.69%)
$SPX : 7,354.02 (-0.05%)
NKE : 40.75 (-0.37%)
GS : 1,019.61 (-4.27%)
AMGN : 358.33 (+1.56%)
MSFT : 372.97 (+5.71%)
CAT : 997.47 (-5.63%)
AXP : 340.36 (-0.61%)
How to Play QNT Stock After the Quantinuum IPO

Quantinuum’s IPO grabbed headlines, but its first trading day showed both excitement and caution. How can investors approach QNT stock after its Wall Street debut?

MITSY : 564.2000 (+3.24%)
EADSY : 54.5000 (-1.25%)
QNT : 75.57 (+5.43%)
HON : 231.46 (+0.10%)
JPM : 329.05 (-1.81%)
MIELY : 72.5700 (-1.05%)
BMWKY : 22.2700 (-2.79%)
AMGN : 358.33 (+1.56%)
Amgen Touts MariTide, AI Gains and 2026 Growth Plans at Jefferies Conference

Amgen (NASDAQ:AMGN) executives used a Jefferies investor conference appearance to emphasize the company’s first-quarter growth, its late-stage pipeline and its preparations for potential launches, including...

AMGN : 358.33 (+1.56%)
AMGEN TO PRESENT AT THE GOLDMAN SACHS 47TH ANNUAL GLOBAL HEALTHCARE CONFERENCE

THOUSAND OAKS, Calif. , June 4, 2026 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the Goldman Sachs 47 th  Annual Global Healthcare Conference at 9:20 a.m. ET on Tuesday, June 9, 2026. Peter...

AMGN : 358.33 (+1.56%)
Honeywell Stock Is Likely to Reward Shareholders Following Quantinuum IPO, Split

HON will own a large stake in Quantinuum following the IPO.

EADSY : 54.5000 (-1.25%)
SNDK : 2,090.71 (-10.46%)
HON : 231.46 (+0.10%)
JPM : 329.05 (-1.81%)
ILMN : 176.55 (-0.62%)
WDC : 586.45 (-13.17%)
GRAL : 65.85 (-1.08%)
GEV : 1,045.17 (-3.71%)
BMWKY : 22.2700 (-2.79%)
AMGN : 358.33 (+1.56%)
GE : 369.00 (-0.64%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Amgen Inc. is the leading biotech companies world wide, with a strong presence in the oncology/hematology, cardiovascular disease, neuroscience, inflammation, bone health & nephrology and neuroscience markets. It developed two most successful drugs, Epogen & Neupogen. Amgen successfully launched two...

See More

Key Turning Points

3rd Resistance Point 366.97
2nd Resistance Point 363.03
1st Resistance Point 357.93
Last Price 358.33
1st Support Level 348.89
2nd Support Level 344.95
3rd Support Level 339.85

See More

52-Week High 391.29
Last Price 358.33
Fibonacci 61.8% 344.87
Fibonacci 50% 330.53
Fibonacci 38.2% 316.19
52-Week Low 269.77

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.